Belluscura beats forecasts
By HME News Staff
Updated 8:35 AM CST, Tue January 25, 2022
LONDON and PLANO, Texas – Belluscura has sold 377 X-PLO2R portable oxygen concentrators since the launch of the device in September 2021, 25% above current consensus forecasts and 150% above initial forecasts for 2021, according to the company’s board of directors.
“Market reception for the X-PLO2R has been positive and initial demand has been very strong,” said Robert Raulker, CEO. “We are very excited about the upcoming launch of the X-PLO2R and X-PLO2 DX and look to the future with confidence.”
Belluscura expects to launch the X-PLO2R CX and X-PLO2 DX in the second and third quarters, respectively.
The company says it has significantly increased inventory levels of key components and other raw materials to pre-empt any potential disruption on production levels due to supply chain challenges. It has also scaled up its manufacturing capability significantly to ensure it can meet increased demand.
Belluscura expects to release preliminary financial results for 2021 in mid-February. As of Dec. 31, 2021, it retained cash balances of $15.6 million and remained debt free.
Comments